41. Anticoagulant, Antiplatelet, and Thrombolytic Drugs

  1. Kandice Kottke-Marchant MD, PhD4,5,6 and
  2. Bruce H. Davis MD7
  1. Laura Green MBBS, MRCP, FRCPath1 and
  2. Samuel J. Machin MD, FRCP, FRCPath2,3

Published Online: 8 AUG 2012

DOI: 10.1002/9781444398595.ch41

Laboratory Hematology Practice

Laboratory Hematology Practice

How to Cite

Green, L. and Machin, S. J. (2012) Anticoagulant, Antiplatelet, and Thrombolytic Drugs, in Laboratory Hematology Practice (eds K. Kottke-Marchant and B. H. Davis), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444398595.ch41

Editor Information

  1. 4

    Pathology & Laboratory Medicine Institute, Cleveland, OH, USA

  2. 5

    Department of Pathology, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA

  3. 6

    Hemostasis and Thrombosis, Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA

  4. 7

    Trillium Diagnostics, LLC, Bangor, ME, USA

Author Information

  1. 1

    Department of Haematology, Barts and The London NHS Trust, London, UK

  2. 2

    University College London, London, UK

  3. 3

    University College London Hospitals, London, UK

Publication History

  1. Published Online: 8 AUG 2012
  2. Published Print: 10 APR 2012

ISBN Information

Print ISBN: 9781405162180

Online ISBN: 9781444398595



  • antithrombotic;
  • antiplatelet;
  • thrombolytics;
  • anticoagulants


Arterial and venous thrombosis is the leading cause of mortality and morbidity in the developed world; effective antithrombotic therapies are an important part of their management. The limitations of the old antithrombotic agents and the continuous advances in the understanding of the hemostatic process have led to the development of novel agents and the publication of some of the largest clinical trials in the field of antithrombotic therapy in the last 20 years. The multiplicity of available agents has increased the complexity of the management of thrombotic conditions; above all, a delicate balance needs to be maintained between reducing the occurrence of thrombotic events and minimizing the bleeding risk. This chapter will provide an overview of the most commonly used antiplatelet, anticoagulant, and thrombolytic agents in clinical practice.